KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent
(2) NEW YORK CITY (dpa-AFX) - Todays Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizers Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovids investigational medicine Soticlestat. Read on. 1.KemPharm Scores FDA Nod For ADHD Drug KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FD...
Takeda Shonan Johnson Concerta Ovid Soticlestat Vir Biotechnology Inc Magenta Therapeutics Inc Corium Inc
Source: finanznachrichten.de